Marketing and selling expenses decreased $1. 5 million from the second quarter cialis tadalafil of 2002, to $1.
2 million in the second quarter cialis tadalafil of 2003.
ICOS is currently conducting Phase 2 clinical studies with RTX, in patients with interstitial cystitis, and IC14, for the treatment of sepsis resulting from community acquired pneumonia. In previous studies, other herbal supplements have been found to vary considerably in composition, suggesting quality control problems (SN: 6/7/03, p. By the end of 2003, in major markets in Europe, Cialis had successfully captured a significant share of unit (tablet) sales among the three PDE5 inhibitors -- Cialis, Viagra(R) (sildenafil) cialis tadalafil and Levitra(R) (vardenafil). Timeline for Cialis, Lilly ICOS will conduct discussions with the FDA on the Cialis tadalafil exact data requirements requested by the agency for final product approval. Cialis Global Launch Update Since the launch in February 2003, Cialis cialis tadalafil has captured a significant share of unit (tablet) sales among the three PDE5 inhibitors (Cialis, Viagra and Levitra(R)(2) (vardenafil))(3). For intercourse attempts at 24 hours, 53 percent were successful for cialis tadalafil patients on Cialis versus 29 percent for those on placebo (P less than 0. Lilly ICOS' 2005 second quarter net loss narrowed to $1. 7 million, compared to $41. 7 million in cialis tadalafil the 2005 first quarter. Such forward-looking statements are based on current expectations, estimates and projections about the industry, management beliefs and certain assumptions made by the management.

Cialis tadalafil in June 2005, and 31. 2% in the aggregate, across Europe, Cialis tadalafil canada and Mexico, in June 2005. "(2) Financial Results For the three months ended June 30, 2005, ICOS reported a net loss of $22.

6 million ($0.
35 per Cialis tadalafil share), compared to a net loss of $51. 9 million ($0.
82 cialis tadalafil per share) for the three months ended June 30, 2004. (formerly Texas Biotechnology Corporation). We Cialis tadalafil are delighted with the high physician and patient awareness of Cialis so soon after the product launch, stated ICOS Chairman and Chief Executive Officer, Paul Clark. (formerly Texas Biotechnology Corporation), partially offset by higher cost reimbursement revenue from Lilly ICOS. The Company applies its integrated approach to erectile dysfunction and other urologic disorders, sepsis, pulmonary arterial hypertension and other cardiovascular diseases, and inflammatory diseases. The number of markets where cialis tadalafil cialis is available continues to grow. Total third quarter sales of Cialis included cialis tadalafil $26. 1 million in Europe and $2. 3 million in Mexico. This combination could also cause Cialis tadalafil a significant drop in blood pressure. We are very pleased to report a year of significant accomplishments, said Chairman and Chief Executive Officer, Paul Clark. Additionally, a webcast will cialis tadalafil be available live at http://media. Corporate-ir. Net/media_files/nsd/icos/call. Htm and archived until May 3. ICOS' strategy targets multiple therapeutic areas with drugs that act through distinct molecular mechanisms, increasing ICOS' opportunities to market breakthrough products.